Traws Pharma, Inc. (TRAW)
| Market Cap | 13.58M |
| Revenue (ttm) | 226,000 |
| Net Income (ttm) | -140.79M |
| Shares Out | 3.03M |
| EPS (ttm) | -141.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,788 |
| Open | 4.700 |
| Previous Close | 4.710 |
| Day's Range | 4.155 - 4.700 |
| 52-Week Range | 4.155 - 27.500 |
| Beta | 1.41 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About TRAW
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-k... [Read more]
Financial Performance
In 2023, Traws Pharma's revenue was $226,000, a change of 0.00% compared to the previous year's $226,000. Losses were -$18.95 million, -0.08% less than in 2022.
Financial numbers in USD Financial StatementsNews
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
NEWTOWN, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral disease...
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability res...
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws' Further Transformation and Growth
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws' shares expected to begin trading on a split-adjust...
Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript
Traws Pharma, Inc. (NASDAQ:TRAW) Corporate Update Call August 15, 2024 8:00 AM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Werner Cautreels - CEO Mark Guerin - CFO Conference Call Par...
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical ...
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral disease...
Traws Pharma Announces New Employee Inducement Grants
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection ...
Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024
NEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develo...
Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's
Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compa...
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference
NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developin...
Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Steve Fruchtman - President and CEO Vi...
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational ...
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develop...
Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL
Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models
Onconova Expands Leadership Team with Two Key Appointments
Dr. Victor Moyo named Chief Medical Officer Meena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX...
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023 Additional studies support broad potential, especially in cyclin-dependent cancers
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developi...
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developi...
Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Steve Fruchtman - President and CEO ...
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care Narazaciclib ...
Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa Trial in Progr...
Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Bruce Mackle - Managing Director, LifeSci Advisors Steven Fruchtman - President...
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
NEWTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel produc...